Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Do not use in dogs with moderate or severe systemic disease (graded as ASA III or greater), e.g.
moderate to severe renal, liver or cardiovascular disease.
Do not use in dogs obviously sedated (shows signs of e.g. drowsiness,
uncoordinated movements, decreased responsiveness) from previous dosing.
Use during pregnancy, lactation or lay
Laboratory studies in rats have shown evidence of developmental toxicity at
maternotoxic doses causing clear sedation-related clinical signs, decreased food
consumption, and decreased body weight gain of the dam.
The safety of the veterinary medicinal product has not been established during
pregnancy and lactation in the target species.
Do not use during pregnancy and lactation.
Interaction with other medicinal products and other forms of interaction
The safety of tasipimidine in combination with tricyclic antidepressant clomipramine
(1.2-2.0 mg/kg), serotonin reuptake inhibitor fluoxetine (1.1-1.6 mg/kg), anaesthesia
premedications (dexmedetomidine, methadone), induction agents (propofol) and
inhalation anaesthetics (isoflurane) has been demonstrated in small-scale studies (N
= 4-7) in laboratory dogs. When used concomitantly with clomipramine or fluoxetine,
the tasipimidine dose should be reduced to 20 μg/kg bodyweight.
The use of other central nervous system depressants is expected to potentiate the
effects of tasipimidine and therefore an appropriate dose adjustment should be
made.